Despite the clinical challenges experienced by patients with PNH receiving treatment with C5 inhibitors, limited real-world evidence on HRU and healthcare costs exists in the US outside of these two studies, with limited sample size. This evidence concerns the gene C5 and paroxysmal nocturnal hemoglobinuria.